Foresite Capital Fund V L.P. 13D and 13G filings for Theseus Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-11-24 4:23 pm Unchanged |
2023-11-22 | 13D | Theseus Pharmaceuticals, Inc. THRX |
Foresite Capital Fund V L.P. | 5,494,621 12.400% |
0 (Unchanged) |
Filing |
| 2023-07-19 2:41 pm Purchase |
2023-03-09 | 13D | Theseus Pharmaceuticals, Inc. THRX |
Foresite Capital Fund V L.P. | 5,494,621 12.600% |
700,000 (+14.60%) |
Filing |
| 2023-01-03 4:36 pm Purchase |
2022-12-29 | 13D | Theseus Pharmaceuticals, Inc. THRX |
Foresite Capital Fund V L.P. | 4,794,621 12.400% |
500,000 (+11.64%) |
Filing |
| 2022-06-13 4:24 pm Purchase |
2022-06-09 | 13D | Theseus Pharmaceuticals, Inc. THRX |
Foresite Capital Fund V L.P. | 4,294,621 11.100% |
613,069 (+16.65%) |
Filing |
| 2021-10-18 1:15 pm Purchase |
2021-10-07 | 13D | Theseus Pharmaceuticals, Inc. THRX |
Foresite Capital Fund V L.P. | 3,681,552 9.800% |
3,681,552 (New Position) |
Filing |